Suppr超能文献

获得性血管性血友病综合征与甲状腺功能减退时纤溶酶原激活物及其抑制剂减少有关。

Acquired von Willebrand's syndrome associated with decrease of plasminogen activator and its inhibitor during hypothyroidism.

作者信息

Levesque H, Borg J Y, Cailleux N, Vasse M, Daliphard S, Gancel A, Monconduit M, Courtois H

机构信息

Service de Médecine Interne, Centre Hospitalier Universitaire de Rouen-Boisguillaume, France.

出版信息

Eur J Med. 1993 May;2(5):287-8.

PMID:8252160
Abstract

OBJECTIVES

In a prospective study we searched for von Willebrand's syndrome during hypothyroidism and investigated the effects of treatment with thyroid hormones on plasma concentrations or activities of the factors involved in von Willebrand's disease in addition to tissue plasminogen activator and plasminogen activator inhibitor 1.

METHODS

Eleven patients with hypothyroidism were tested. Factor VIII coagulant activity (VIIIc), von Willebrand factor (vWf:Ag), von Willebrand factor activity (vWf:RCo), tissue plasminogen activator antigen (tPA) and plasminogen activator inhibitor activity (PAI) was monitored before and after correction of hypothyroidism by hormone supplementation.

RESULTS

Five patients had laboratory evidence of type I von Willebrand's disease. The other six patients had concentrations or activities of the factors involved in von Willebrand's disease within the normal range. In all cases except one, during thyroxin treatment, von Willebrand factors returned to normal if initially low, or increased clearly if initially normal. With the correction of hypothyroidism, an increase of tPA was noted in the eleven patients, associated with a significant increase of PAI.

CONCLUSION

Laboratory evidence of von Willebrand's disease is common during hypothyroidism. Study of plasminogen activator and its inhibitor suggest a decrease of von Willebrand factor synthesis during hypothyroidism.

摘要

目的

在一项前瞻性研究中,我们在甲状腺功能减退症患者中筛查血管性血友病综合征,并研究甲状腺激素治疗对血管性血友病相关因子的血浆浓度或活性的影响,同时观察组织型纤溶酶原激活剂和纤溶酶原激活剂抑制剂1的变化。

方法

对11例甲状腺功能减退症患者进行检测。在通过补充激素纠正甲状腺功能减退症之前和之后,监测因子VIII凝血活性(VIIIc)、血管性血友病因子(vWf:Ag)、血管性血友病因子活性(vWf:RCo)、组织型纤溶酶原激活剂抗原(tPA)和纤溶酶原激活剂抑制剂活性(PAI)。

结果

5例患者有I型血管性血友病的实验室证据。其他6例患者血管性血友病相关因子的浓度或活性在正常范围内。除1例患者外,在所有病例中,甲状腺素治疗期间,如果血管性血友病因子最初较低,则会恢复正常;如果最初正常,则会明显升高。随着甲状腺功能减退症的纠正,11例患者的tPA增加,同时PAI显著增加。

结论

血管性血友病的实验室证据在甲状腺功能减退症患者中很常见。对纤溶酶原激活剂及其抑制剂的研究表明,甲状腺功能减退症期间血管性血友病因子的合成减少。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验